[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unruptured-brain-arteriovenous-malformation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unruptured-brain-arteriovenous-malformation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636761","exploratory-study-of-cerebral-perfusion-and-metabolic-alterations-and-neurocognitive-disorders-in-patients-with-unruptured-arteriovenous-malformations-before-and-after-surgical-treatment-100636761",false,"NCT07569887","Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment","APEMMAV-NR","Inclusion Criteria:\n\n* Adults aged 18 and older\n* Admitted for an unruptured arteriovenous malformation with a decision to proceed with surgery\n\nExclusion Criteria:\n\n* Patients who refuse surgical treatment for arteriovenous malformation\n* Contraindications to 18F-FDG PET (uncontrolled diabete)\n* Patients' inability to lie still for 40 minutes\n* Patients with a confirmed diagnosis of neurodegenerative or psychiatric disorders\n* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)\n* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)\n* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)\n* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)\n* Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)\n* Failure to obtain written informed consent","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of the clinical trial is to describe perfusion and metabolic alterations in different brain regions before and six months after surgical treatment of arteriovenous malformations in adult patients with unruptured arteriovenous malformations.",[26],"Unruptured Brain Arteriovenous Malformation",[28,29,30,31,32],"Arteriovenous malformation","Perfusion disorders","Metabolism","Positon Emission Tomography","Neuropathology","NOT_YET_RECRUITING","2026-05-04",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":20},"2026-05",{"date":41,"type":20},"2028-11",{"name":43,"class":44},"University Hospital, Montpellier","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100216702","treatment-of-brain-avms-tobas-study-100216702","NCT02098252","Treatment of Brain AVMs (TOBAS) Study","Treatment of Brain AVMs (TOBAS) Study: A Randomized Controlled Trial and Registry","TOBAS","Inclusion Criteria:\n\n* Any patient with a brain AVM\n\nExclusion Criteria:\n\n* Hemorrhagic presentation with mass effect requiring surgical management. In these cases, if a residual AVM is found after the initial surgery, the patient could then be a candidate for TOBAS.","5 Years",{"count":56,"type":20},1000,[23],"The objectives of this study and registry are to offer the best management possible for patients with brain arteriovenous malformations (AVMs) (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty. Management may include interventional therapy (with endovascular procedures, neurosurgery, or radiotherapy, alone or in combination) or conservative management.\n\nThe trial has been designed to test a) whether medical management or interventional therapy will reduce the risk of death or debilitating stroke (due to hemorrhage or infarction) by an absolute magnitude of about 15% (over 10 years) for unruptured AVMs (from 30% to 15%); and, b) to test if endovascular treatment can improve the safety and efficacy of surgery or radiation therapy by at least 10% (80% to 90%).\n\nAs for the nested trial on the role of embolization in the treatment of Brain AVMs by other means: the pre-surgical or pre-radiosurgery embolization of cerebral AVMs can decrease the number of treatment failures from 20% to 10%. In addition,embolization of cerebral AVMs can be accomplished with an acceptable risk, defined as permanent disabling neurological complications of 8%.",[26,60,61,62,63],"Ruptured Brain Arteriovenous Malformation","Arteriovenous Malformations","AVM","BAVM",[65,61,62,63,66,67,68,69,70,71,72,73],"brain arteriovenous malformation","Stroke","Intracranial Hemorrhage","Congenital Abnormalities","Aneurysm","Vascular Malformations","Cardiovascular Abnormalities","Cardiovascular Diseases","Vascular Diseases","RECRUITING","2024-08-13",{"date":77,"type":37},"2024-08-15",{"date":79,"type":4},"2014-05",{"date":81,"type":20},"2036-01",{"name":83,"class":44},"Centre hospitalier de l'Université de Montréal (CHUM)",30]